Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles

IF 4.2 3区医学 Q2 ENGINEERING, BIOMEDICAL

Journal of Materials Science: Materials in Medicine Pub Date : 2023-08-31 DOI:10.1007/s10856-023-06748-w

Mehrdad Moosazadeh Moghaddam, Shahin Bolouri, Reza Golmohammadi, Mahdi Fasihi-Ramandi, Mohammad Heiat, Reza Mirnejad

{"title":"Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles","authors":"Mehrdad Moosazadeh Moghaddam, Shahin Bolouri, Reza Golmohammadi, Mahdi Fasihi-Ramandi, Mohammad Heiat, Reza Mirnejad","doi":"10.1007/s10856-023-06748-w","DOIUrl":null,"url":null,"abstract":"<div><p><i>Helicobacter pylori</i> is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of <i>H. pylori</i> is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of <i>H. pylori</i> infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target <i>H. pylori</i>. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against <i>H. pylori</i> SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of <i>H. pylori SS1</i> strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against <i>H. pylori SS1</i> strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of <i>H. pylori</i> SS1 strain.</p><h3>Graphical Abstract</h3>\n <div><figure><div><div><picture><img></picture></div></div></figure></div>\n </div>","PeriodicalId":647,"journal":{"name":"Journal of Materials Science: Materials in Medicine","volume":"34 9","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471652/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Materials Science: Materials in Medicine","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s10856-023-06748-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Helicobacter pylori is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of H. pylori is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of H. pylori infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target H. pylori. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against H. pylori SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of H. pylori SS1 strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against H. pylori SS1 strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of H. pylori SS1 strain.

Graphical Abstract

Abstract Image

查看原文本刊更多论文

使用刀豆蛋白a包被的壳聚糖纳米颗粒靶向递送抗幽门螺杆菌胃感染的短抗菌肽（CM11）。

幽门螺杆菌是大多数胃溃疡的病因，也会导致一些消化道癌症。幽门螺杆菌抗生素耐药性菌株的出现和传播是治疗其感染的最重要挑战之一。本研究旨在开发一种基于刀豆球蛋白a（ConA）包被的壳聚糖（CS）纳米载体的药物递送，用于将肽靶向释放到幽门螺杆菌感染部位。因此，采用离子凝胶法将壳聚糖用作CM11肽递送的包封剂。Con-A用于包覆CS纳米颗粒以靶向幽门螺杆菌。通过FTIR、动态光散射（DLS）和扫描电子显微镜（SEM）对CS NPs和ConA CS NPs进行了表征。在体外分析了CM11负载的ConA-CS NPs对幽门螺杆菌SS1菌株的MIC。为了评价体内治疗效果，在小鼠中建立了幽门螺杆菌SS1菌株的胃感染模型，并进行了组织病理学研究和IL-1β细胞因子测定。根据结果，CS NP和ConA CS NP的尺寸频率分别约为200和350 nm。所制备的负载CM11的ConA-CS NP对浓度为32的幽门螺杆菌SS1菌株表现出抗菌活性 µg/ml。在合成的CM11负载的ConA-CS NPs治疗中观察到最高的愈合过程，并且观察到IL-1β的显著降低。我们的研究结果强调了壳聚糖纳米粒子作为药物递送载体在治疗幽门螺杆菌SS1菌株胃感染模型中的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Materials Science: Materials in Medicine 工程技术-材料科学：生物材料

CiteScore

8.00

自引率

0.00%

发文量

审稿时长

3.5 months

期刊介绍： The Journal of Materials Science: Materials in Medicine publishes refereed papers providing significant progress in the application of biomaterials and tissue engineering constructs as medical or dental implants, prostheses and devices. Coverage spans a wide range of topics from basic science to clinical applications, around the theme of materials in medicine and dentistry. The central element is the development of synthetic and natural materials used in orthopaedic, maxillofacial, cardiovascular, neurological, ophthalmic and dental applications. Special biomedical topics include biomaterial synthesis and characterisation, biocompatibility studies, nanomedicine, tissue engineering constructs and cell substrates, regenerative medicine, computer modelling and other advanced experimental methodologies.